Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: Behavioural and immunohistochemical studies

European Journal of Neuroscience

Volumn 8, Issue 7, 1996, Pages 1408-1414

  Piallat, Brigitte ^a   Benazzouz, Abdelhamid ^a   Benabid, Alim Louis ^a  

^a INSERM   (France)

Author keywords

Cell death; Neuroprotection; Parkinson's disease; Substantia nigra

Indexed keywords

KAINIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROTOXIN; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DOPAMINERGIC NERVE CELL; IMMUNOREACTIVITY; MALE; NERVE CELL DEGENERATION; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

ANIMALS; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; FUNCTIONAL LATERALITY; IMMUNOHISTOCHEMISTRY; KAINIC ACID; MALE; MOTOR ACTIVITY; NERVE DEGENERATION; OXIDOPAMINE; RATS; RATS, WISTAR; ROTATION; SUBSTANTIA NIGRA; THALAMIC NUCLEI;

EID: 0029897501     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1460-9568.1996.tb01603.x     Document Type: Article

References (27)

1. Aziz, T. Z., Peggs, D., Sambrook, M. A. and Crossman, A. R. (1991) Lesion of the subthalamic nucleus for the alleviation of protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Movement Disorders, 6, 288-292.
2. Aziz, T. Z., Peggs, D., Agarwal, E., Somebrook, M. A. and Crossman, A. R. (1992) Subthalamic nucleotomy alleviates parkinsonism in the l-methyl-4phenyl-l,2,3,6-tetrahydropyridine (MPTP)-exposed primate. Br. J. Neurosurg., 6, 575-582.
3. Beal, M. F., Hyman, B. T. and Koroshetz, W. (1993) Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci., 16, 125-131.
4. Benazzouz, A., Gross, C., Feger, J., Boraud, T. and Bioulac, B. (1993) Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur. J. Neurosci., 5, 382-389
5. Benazzouz, A, Piallat, B., Pollak, P. and Benabid, A. L. (1995) Responses of substantia nigra pars reticulata and globus pallidus complex to high frequency stimulation of the subthalamic nucleus in rats: electrophysiological data. Neurosci. Lett., 189, 77-80.
6. Bergman, H., Wichmann, T. and Delong, M. R. (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science, 249, 1436-1438
7. Brouillet, E. and Beal, M. F. (1993) NMDA antagonists partially protect against MPTP induced neurotoxicity in mice. NeuroReport, 4, 387-390.
8. Burbaud, P., Gross, C., Benazzouz, A., Coussemacq, M. and Bioulac, B. (1995) Reduction of apomorphine-induced rotational behaviour by subthalamic lesion in 6-OHDA lesioned rats is associated with a normalisation of firing rate and discharge pattern of pars reticulata neurons. Exp. Brain Res., 105, 48-58.
9. Greenamyre, J. T. and O'Brien, C. F. (1991) NMDA antagonists in the treatment of Parkinson's disease. Arch. Neurol., 48, 977-981.
10. Hammond, C., Deniau, J. M., Rizk, A. and Feger, J. ( 1978) Electrophysiological demonstration of an excitatory subthalamonigral pathway in the rat. Brain Res., 151, 235-244.
11. Hammond, C., Féger, J., Bioulac, B. and Souteyrand, J. P. (1979) Experimental hemiballism in the monkey produced by unilateral kainic acid lesion in corpus Luysii. Brain Res., 171, 577-580.
12. Halliwell, B. (1992) Reactive oxygen species and the central nervous system. J. Neurochem., 59, 1609-1623.
13. Hattori, N., Tanka, M., Ozawa, T. and Mizuno, Y. (1991) Immunohistological studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease. Ann. Neurol., 30, 563-571.
14. Heikkila, R. and Cohen, G. (1971) Inhibition of biogenic amine uptake by hydrogen peroxide: mechanism for toxic effects of 6-hydroxydopamine. Science. 172, 1257-1258.
15. Hornykiewicz, O. (1982) Brain neurotransmitter changes in Parkinson's disease. In Marsden, C. D. and Fahn, S. (eds), Movement Disorders, Vol. 2. Butterworth Scientific, London, pp. 41-58.
16. Hudson, J. L., van Home, C. G., Strömberg, I., Brock, S., Clayton, J., Masserano, J., Hoffer, B. J. and Gerhardt, G. A. (1993) Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res., 626, 167-174.
17. Ikebe, S., Tanaka, M. and Ozawa, T. (1995) Point mutations of mitochondrial genome in Parkinson's disease. Mol. Brain Res., 28, 281-295.
18. Lange, K. W., Löschmann, P. A., Sofic, E., Burg, M., Horowski, R., Kalveram, K. T., Watchel, H. and Riederer, P. (1993) The competitive NMDA antagonist CPP protects substantia nigra from MPTP-induced degeneration in primates. Arch. Pharmacol., 348, 586-592.
19. Limousin, P., Pollak, P., Benazzouz, A., Hoffmann, D., Lebas, J.-F., Broussole, E., Perret, J. E. and Benabid, A. (1995) Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. The Lancet, 345, 91-95.
20. Marshall, J. F., O'Dell, S. J. and Weihmuller, F. B. (1993) Dopamineglutamate interactions in methamphetamine-induced neurotoxicity. J. Neurol Transm. (Gen. Sect.), 91, 241-254.
21. McKenzie, J. S., Shafton, A. D. and Stewart, C.A. (1987) Motor responses to GABAergic interference in the rat ento-peduncular nucleus in relation to rotation behaviour. In Carpenter, M. B. and Jayarama, A. (eds), The Basal Ganglia. II. Structure and Function - Current Concepts. Advances in Behavioral Biology, Vol. 32. Plenum Press, New York, pp. 327-335.
22. Miller, W. C. and De Long, M. R. (1987) Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In Carpenter, M. B. and Jayaraman (eds). The Basal Ganglia, II. Structure and Function - Current Concepts. Advances in Behavioral Biology, Vol. 32. Plenum Press, New York, pp. 415-427.
23. Mitchell, I. J., Clarke, C. E., Boyce, S., Robertson, R. G., Peggs, D., Sambrook, M. A. and Crossman, A. R. (1989) Neurol mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience, 32, 213-226.
24. Murer, M. G., Sinay, V. and Pazo, J. H. (1995) Turning behavior in rats with unilateral lesion of the subthalamic nucleus: synergism between D1 and D2 receptors. J. Neurol Transm., 100, 123-135.
25. Nicklas, W. J., Vays, I. and Heikkila, R. E. (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci., 36, 2503-2508.
26. Novelli, A., Reilly, J. A., Lysko, P. G. and Henneberry, R. C. (1987) Glutamate becomes neurotoxic via the NMDA receptor when intracellular energy levels are reduced. Brain Res., 451, 205-212.
27. O'Dell, S. J., Weihmuller, F. B. and Marshall, J. F. (1992) MK-801 prevents methamphetamine-induced striatal dopamine damage and reduces extracellular dopamine overflow. In Neurotoxins and Neurodegenerative Disease. Ann. N.Y. Acad. Sci., 648, 317-319.